KLKB1抗体;KLKB1 Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of KLKB1 expression in human plasma lysate.    

  
  

KLKB1 antibodies target the plasma kallikrein enzyme, encoded by the *KLKB1* gene, which plays a critical role in the kallikrein-kinin system (KKS). This serine protease regulates inflammatory responses, blood pressure, coagulation, and fibrinolysis by cleaving kininogens to release vasoactive kinins, such as bradykinin. Dysregulation of KLKB1 activity is implicated in hereditary angioedema (HAE), diabetic complications, hypertension, and thrombosis, making it a therapeutic and diagnostic focus.

KLKB1 antibodies are essential tools for studying the enzyme's expression, localization, and function in physiological and pathological contexts. They are used in techniques like Western blotting, immunohistochemistry, and ELISA to quantify KLKB1 levels in tissues or biofluids. Therapeutic antibodies or inhibitory peptides targeting KLKB1 are under investigation to block excessive kinin production in HAE or inflammation-driven diseases. Additionally, these antibodies aid in exploring KLKB1's interactions with inhibitors (e.g., C1 esterase inhibitor) or its role in cross-activating coagulation Factor XII.

Most KLKB1 antibodies are produced in rabbits or mice using recombinant KLKB1 protein fragments. Specificity and cross-reactivity validation are crucial due to structural similarities among kallikrein family proteases. Advances in recombinant antibody engineering have improved their clinical applicability, including diagnostics for kallikrein-related disorders and monitoring treatment efficacy in trials targeting the KKS pathway.